Modality
Peptide
MOA
SOS1i
Target
WEE1
Pathway
Innate Imm
NASHPompe
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
Mar 2017
→ Dec 2027
Phase 1Current
NCT07436091
358 pts·NASH
2024-01→2027-11·Active
NCT08137418
481 pts·Pompe
2017-03→2027-12·Not yet recruiting
839 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-11-041.6y awayInterim· NASH
2027-12-041.7y awayInterim· Pompe
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Not yet…
P1
Active
Catalysts
Interim
2027-11-04 · 1.6y away
NASH
Interim
2027-12-04 · 1.7y away
Pompe
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07436091 | Phase 1 | NASH | Active | 358 | ACR20 |
| NCT08137418 | Phase 1 | Pompe | Not yet recr... | 481 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |